Cargando…

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19

Detalles Bibliográficos
Autores principales:	Foo, Hong, Phan, Fiona, Bagatella, Melissa, Petrovski, Irene, Nagendra, Vana, Acharya, Priya, Levy, Miriam, Prakoso, Emilia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119519/ https://www.ncbi.nlm.nih.gov/pubmed/37084117 http://dx.doi.org/10.1007/s10096-023-04599-5

Ejemplares similares

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
por: Bryushkova, Ekaterina A., et al.
Publicado: (2022)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

513. Evaluating the safety of baricitinib versus tocilizumab in hospitalized patients with COVID-19
por: Brickel, Kendall, et al.
Publicado: (2023)

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19
por: Aytoda, Priyanka, et al.
Publicado: (2023)

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
por: Kojima, Yuichi, et al.
Publicado: (2022)

Tocilizumab: Cytomegalovirus reactivation and acute hepatitis: case report
Publicado: (2021)

Routine screening of emergency admissions at risk of chronic hepatitis (SEARCH) identifies and links hepatitis B cases to care
por: Jacob, Rachael, et al.
Publicado: (2022)

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
por: Masiá, Mar, et al.
Publicado: (2021)

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Finding Cases of Hepatitis C for Treatment Using Automated Screening in the Emergency Department is Effective, but What Is the Cost?
por: Prince, David Stephen, et al.
Publicado: (2022)

Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19
por: Wey, Emmanuel Q., et al.
Publicado: (2021)

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
por: Gavriilidis, Efstratios, et al.
Publicado: (2022)

Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study
por: Roddy, John, et al.
Publicado: (2022)

Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort
por: Karolyi, Mario, et al.
Publicado: (2022)

Tocilizumab: Hepatitis-B viral reactivation with acute hepatitis following an off-label treatment: case report
Publicado: (2021)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
por: Wong, Carlos K. H., et al.
Publicado: (2022)

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
por: Cherian, Jerin Jose, et al.
Publicado: (2022)

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis
por: Papadopoulou, Charalampia, et al.
Publicado: (2019)

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
por: Cantini, Fabrizio, et al.
Publicado: (2020)

STAT1 Gain-of-Function and Hidradenitis Suppurativa Successfully Managed with Baricitinib
por: Olbrich, Peter, et al.
Publicado: (2023)

Fulminant Liver Failure due to Hepatitis B Reactivation During Treatment With Tocilizumab
por: Sonneveld, Milan J., et al.
Publicado: (2019)

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2023)

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
por: Cantini, Fabrizio, et al.
Publicado: (2020)

Glucocorticoids/siltuximab/tocilizumab: Hepatitis-B reactivation following off-label use: 2 case reports
Publicado: (2021)

Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study
por: Rosas, José, et al.
Publicado: (2022)

Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study
por: Rosas, José, et al.
Publicado: (2022)

Tocilizumab and Baricitinib for Recovery From Acute Exacerbation of Combined Pulmonary Fibrosis and Emphysema Secondary to COVID-19 Infection: A Case Report
por: Kai, Yoshiro, et al.
Publicado: (2022)

REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS
por: WILLIAMS, STEPHANIE N, et al.
Publicado: (2022)

Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis
por: Albuquerque, Arthur M., et al.
Publicado: (2023)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment
por: Kuo, Meng Hsuan, et al.
Publicado: (2021)

Cytomegalovirus Viremia, Pneumonitis, and Tocilizumab Therapy
por: van Duin, David, et al.
Publicado: (2011)

Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study
por: Lakatos, Botond, et al.
Publicado: (2022)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Baricitinib for the Treatment of Alopecia Areata
por: Freitas, Egídio, et al.
Publicado: (2023)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Throat swelling following tocilizumab infusion—not always angioedema
por: Baenziger-Sieber, Patricia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c736bobvg9jnbn8hkkc48kebsn